Hikal Ltd Upgraded to Hold by MarketsMOJO Amid Mixed Financial and Technical Signals

Technical Trends Shift to Mildly Bullish

The primary catalyst for the rating upgrade stems from a positive shift in Hikal’s technical profile. The technical trend has moved from a sideways pattern to a mildly bullish stance, supported by several key indicators. On a weekly basis, the Moving Average Convergence Divergence (MACD) is bullish, while the monthly MACD remains bearish, indicating some divergence in momentum across timeframes. The Relative Strength Index (RSI) shows no clear signal on both weekly and monthly charts, suggesting a neutral momentum.

Bollinger Bands on the weekly chart have turned mildly bullish, contrasting with a bearish monthly outlook. Daily moving averages are bullish, reinforcing short-term upward momentum. The Know Sure Thing (KST) indicator is bullish weekly but bearish monthly, while Dow Theory signals no trend weekly and a mildly bullish trend monthly. On-balance volume (OBV) shows no trend weekly but bullish monthly, hinting at accumulation over the longer term.

These mixed but improving technical signals have encouraged analysts to revise the technical grade upwards, reflecting a more constructive near-term price action outlook despite some caution on longer-term momentum.

Valuation Remains Attractive Amidst Discount to Peers

Hikal’s valuation metrics continue to favour a Hold rating. The company’s Return on Capital Employed (ROCE) stands at a modest 3%, yet it benefits from an attractive Enterprise Value to Capital Employed ratio of 1.8. This suggests the stock is trading at a discount relative to its peers’ historical valuations, offering potential value for investors willing to look beyond short-term volatility.

Despite a recent share price decline—closing at ₹217.05 on 29 July 2026, down 2.27% from the previous close of ₹222.10—the stock remains well above its 52-week low of ₹145.95, though significantly below its 52-week high of ₹336.10. This wide trading range reflects market uncertainty but also highlights the potential for upside if fundamentals improve further.

Financial Trend Shows Mixed Signals with Recent Quarterly Strength

Hikal’s financial trend presents a complex picture. The company reported a strong performance in Q4 FY25-26, with Profit Before Tax Less Other Income (PBT LESS OI) reaching ₹48.80 crores, representing an extraordinary growth of 1345.9% compared to the previous four-quarter average. This surge is a significant positive development, signalling operational improvements and better cost management.

Additionally, the company’s debt-equity ratio at half-year stands at a low 0.57 times, reflecting a conservative capital structure. The operating profit to interest ratio has also improved markedly to 7.22 times, indicating enhanced ability to service debt obligations. These factors contribute to a more favourable financial trend assessment, supporting the upgrade to Hold.

However, longer-term fundamentals remain weak. Over the past five years, Hikal’s operating profits have declined at a compound annual growth rate (CAGR) of -24.95%, and the company’s average Return on Equity (ROE) is a modest 7.60%, signalling limited profitability per unit of shareholder funds. The Debt to EBITDA ratio remains elevated at 3.10 times, suggesting some leverage risk.

Profitability challenges are further underscored by a 60% fall in profits over the past year, while the stock has generated a negative return of -32.93% over the same period. This underperformance extends to a three-year horizon, where the stock has lagged the BSE500 benchmark consistently.

Long-Term Performance and Market Comparison

Hikal’s stock returns have been disappointing relative to the broader market. Over one week, the stock declined by 3.55%, underperforming the Sensex’s 0.91% drop. Over one month, however, it posted a modest gain of 1.09%, outperforming the Sensex’s -0.43%. Year-to-date, the stock is down 4.34%, though this is less severe than the Sensex’s -9.92% decline.

Longer-term returns paint a bleaker picture. Over one year, the stock’s -32.93% return starkly contrasts with the Sensex’s -5.10%. Over three and five years, Hikal’s returns of -23.59% and -59.26% respectively lag far behind the Sensex’s positive 16.03% and 46.38%. Even over a decade, while Hikal has delivered a respectable 79.23% return, it remains well below the Sensex’s 172.14% gain.

This persistent underperformance highlights the challenges the company faces in regaining investor confidence and improving its competitive position within the Pharmaceuticals & Biotechnology sector.

Quality Assessment and Shareholder Structure

Hikal’s quality rating remains moderate, reflected in its Mojo Grade of Hold. The company’s operational metrics show some improvement, but the weak long-term growth and profitability metrics temper enthusiasm. The low ROCE and ROE figures indicate that the company is yet to fully capitalise on its capital base and shareholder equity.

Promoters remain the majority shareholders, which typically provides stability in governance and strategic direction. However, the company’s small-cap status and sector volatility require investors to maintain a cautious stance.

Conclusion: A Cautious Upgrade Reflecting Mixed Signals

The upgrade of Hikal Ltd’s investment rating from Sell to Hold is driven primarily by an improved technical outlook and encouraging quarterly financial results. The stock’s valuation remains attractive relative to peers, and debt metrics have improved, signalling better financial health. Nonetheless, persistent long-term fundamental weaknesses, including declining operating profits and underwhelming returns, justify a cautious stance.

Investors should monitor upcoming quarterly results and sector developments closely, as sustained improvements in profitability and operational efficiency will be necessary to warrant a further upgrade. For now, Hikal represents a stock with potential value but also notable risks, making it suitable for investors with a moderate risk appetite and a focus on recovery plays within the pharmaceuticals space.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →